Clinical Study
Testing the Study Drug TN-201 in Adults with Symptomatic MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy
Symptomatic MYBPC3 (a gene found in the muscle of the heart) mutation-associated non-obstructive hypertrophic cardiomyopathy is one of the most common inherited cardiac (heart) diseases. This study will test a drug called TN-201 to treat adults with this disease. The study wants to see if the drug will help people with this disease and is safe. The study will have 2 groups of people receiving different doses of the study drug. All participants will receive the study drug. The drug is given as an infusion (liquid drug given under the skin). Being in the study requires meeting in person at a study clinic at different periods of time over 5 years. Participants will receive payment for participation. Medical tests will be done to track the health of participants.
For more information contact:
Grecia Gutierrez
grecia.gutierrez@hsc.utah.edu
801-585-6163
IRB#: IRB_00166206
| PI: Omar Wever Pinzon
| Department: DIV OF CARDIOVASCULAR MEDICINE
| Approval Date: 2024-01-24 07:00:00
Study Categories: Cardiovascular Studies
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 to 65 years old
- Diagnosis of non-obstructive hypertrophic cardiomyopathy
- Willing to stop drinking alcohol during study participation
- Able to attend in person at a study clinic
Exclusion Criteria:
- Known allergy to the study drug or any part of the study drug
- Active infection
- Scheduled or planning for a major surgery
- History of hepatitis B or hepatitis C
- Pregnant
Will I be paid for my time?
Yes